atrial fibrillation Archives
VHVI offers latest therapies to treat atrial fibrillation
Sep. 9, 2021—Vanderbilt Heart and Vascular Institute continues to offer the latest in therapies to treat atrial fibrillation (AF or AFib), the most common cardiac arrhythmia.
Device to treat AFib may eliminate need for blood thinners
Mar. 18, 2021—Vanderbilt University Medical Center is participating in a trial for a device that could revolutionize the way patients are treated for atrial fibrillation (AF or AFib.)
Genotype looms large in risk for post-op arrhythmia
Mar. 11, 2021—Postoperative atrial fibrillation (PoAF), a form of arrhythmia, complicates 20-40% of cardiac surgical procedures and 10–20% of non-cardiac thoracic operations, cropping up two to four days after surgery to pose risk of stroke, heart attack, mortality, longer hospital stays and greater cost.
Minimally invasive treatment option for AFib studied
Oct. 22, 2020—A minimally invasive procedure that combines ligation of the left atrial appendage (LAA) with hybrid epicardial-endocardial ablation is a feasible, safe and effective method of treating patients with longstanding atrial fibrillation (AF or AFib), according to a new Vanderbilt-led study.
Device helps heart patients ditch blood thinners
Feb. 7, 2019—For the first time in 27 years, Jerry Flowers is looking at life without using blood thinners, thanks to a small device that was implanted in his heart in a clinical trial at Vanderbilt Heart and Vascular Institute (VHVI).
Research bolsters thyroid function, atrial fibrillation link
Jan. 31, 2019—A study by researchers at Vanderbilt University Medical Center has strengthened the link between thyroid function and atrial fibrillation (AF), an irregular heart rhythm that increases the risk of stroke and other heart-related complications.
VUMC joins research network to fight atrial fibrillation
Jun. 14, 2018—Vanderbilt University Medical Center (VUMC) has been selected by the American Heart Association (AHA) to participate in a six-member research network to advance treatment and prevention of atrial fibrillation (AFib), an irregular heart rate that increases the risk of stroke and other heart-related complications.
Multiple options help atrial fibrillation patients
Feb. 22, 2018—Since launching its program offering patients with non-valvular atrial fibrillation (AF) an alternative treatment to reduce their risk of stroke and avoiding long-term use of blood thinners, the Vanderbilt Heart and Vascular Institute (VHVI) has consistently ranked among the top centers in the country for the implantation of left atrial appendage closure (LAAC) devices.
VUMC testing device to reduce stroke risk in arrhythmia patients
Feb. 9, 2017—Vanderbilt University Medical Center (VUMC) is the first in the state to enroll patients in a clinical trial testing the effectiveness of the newest implantable device used to reduce stroke risk in patients with non-valvular atrial fibrillation (AF), the most common form of arrhythmia.
Device helps curb atrial fibrillation patients’ stroke risk
Aug. 25, 2016—Peggy Tubb doesn’t recall her exact reaction when she was told she could stop taking blood thinners to treat atrial fibrillation (AF), but the news changed her life.
Risk of death in the ICU
Oct. 15, 2015—The irregular heart rhythm atrial fibrillation increases the risk of death in patients in the intensive care unit.
Vanderbilt Heart offers alternative to blood thinners for atrial fibrillation
Jun. 17, 2015—Vanderbilt Heart and Vascular Institute now offers patients with atrial fibrillation (AF) an alternative treatment to reduce their risk of stroke, potentially avoiding the long-term use of blood thinners such as warfarin.
